Semaglutide Pharmacokinetics

Structural basis for the long half-life

Two engineered features of Semaglutide dominate its pharmacokinetic profile. First, α-aminoisobutyric acid at position 8 (Aib8) renders the peptide resistant to dipeptidyl peptidase-4 (DPP-4), the serine protease that cleaves native GLP-1 between His7 and Ala8 within one to two minutes.^[1] Second, a C18 fatty-di-acid attached at Lys26 through a γGlu-2xOEG spacer supports reversible non-covalent binding to serum albumin at fatty acid binding sites.^[2]

Albumin binding and distribution

Albumin binding of Semaglutide is high — greater than 99% in reported plasma. Albumin acts as a slow-release reservoir: only the small unbound fraction is pharmacologically active at the GLP-1 receptor, but the bound fraction is protected from renal filtration and from most proteolytic clearance pathways. This reservoir behaviour is the primary determinant of the extended half-life.^[2] Distribution is largely confined to the vascular and interstitial compartments consistent with an albumin-bound peptide.

Subcutaneous absorption

After subcutaneous administration, Semaglutide is absorbed slowly from the injection depot. Peak plasma concentrations are reached over one to three days, with high bioavailability. Because the plasma half-life is close to one week, once-weekly dosing produces approximately three- to five-fold accumulation before steady state, which is reached over roughly four to five weeks of consistent weekly dosing.^[2]

Oral absorption and SNAC

Oral Semaglutide (marketed as Rybelsus) is co-formulated with SNAC — sodium N-[8-(2-hydroxybenzoyl)amino]caprylate. SNAC transiently raises local pH in the stomach, reducing peptic degradation, and interacts with the gastric epithelium in a way that supports transcellular absorption of a small fraction of the dose.^[9] Oral bioavailability is low (approximately 1%), which is why oral doses are numerically much larger than subcutaneous doses; the resulting plasma concentrations are pharmacologically comparable.

Elimination

Semaglutide is cleared primarily through proteolytic degradation of both the peptide backbone and the fatty-acid side chain, with metabolites excreted via urine and faeces. Renal impairment does not markedly alter total exposure in reported studies, consistent with proteolysis rather than renal filtration being the dominant clearance mechanism.

Research use vs approved therapeutic context

The pharmacokinetics summarised here derive from published human and preclinical studies of Semaglutide administered as an approved therapeutic (Ozempic, Wegovy, Rybelsus) under MHRA and FDA authorisation. Oxford Research Peptides supplies Semaglutide as a reference standard for in-vitro laboratory research only — in-vivo pharmacokinetic parameters are contextual scientific information and do not describe or endorse any human use of research-grade material.

Related reading: Semaglutide monograph, What is Semaglutide, Semaglutide mechanism of action, GLP-1 receptor explained, Retatrutide monograph, Triple agonists explained, Research Use Only and Testing & Quality Control.